Evaluation of bioavailability upon oral administration of phytonadione preparations in beagle dogs. 1993

T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.

Bioavailability of phytonadione was investigated after oral administration to beagle dogs. The administrations of phytonadione in a surfactant solution (preparation a) and in an oleic acid solution (preparations b) greatly increased the bioavailability of phytonadione. The AUCs of preparations a and b were about 2.5 times larger than those of commercially available tablets A and C. This result well corresponded to the results of the dissolution test previously reported. The absorption of phytonadione from the gastro-intestinal tract was affected by food and the bioavailability was largely increased under non-fasted conditions. However, a large scatter was observed in the data, and it was found that the evaluation of the bioavailability of phytonadione preparations could not be done in non-fasted animals.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008297 Male Males
D009829 Oleic Acids A group of fatty acids that contain 18 carbon atoms and a double bond at the omega 9 carbon. Octadecenoic Acids,Acids, Octadecenoic,Acids, Oleic
D010837 Vitamin K 1 A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity. Phylloquinone,Phytomenadione,Phytonadione,Aquamephyton,Konakion,Phyllohydroquinone,Vitamin K1
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005079 Excipients Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. Excipient,Stabilizing Agent,Stabilizing Agents,Suspending Agent,Suspending Agents,Agent, Stabilizing,Agent, Suspending,Agents, Stabilizing,Agents, Suspending
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
October 2008, Drug development and industrial pharmacy,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
January 1969, Antimicrobial agents and chemotherapy,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
October 2018, Pharmaceutics,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
September 2011, Veterinary journal (London, England : 1997),
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
January 2013, Current pharmaceutical biotechnology,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
June 1982, Chemical & pharmaceutical bulletin,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
January 1980, Journal of environmental pathology and toxicology,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
May 1997, Journal of pharmaceutical sciences,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
May 2009, Archives of pharmacal research,
T Tokumura, and Y Tsushima, and Y Machida, and M Kayano, and T Nagai
December 2022, Veterinary dermatology,
Copied contents to your clipboard!